Genmab — April 2019

[polle1]

Som jeg sagde igår, så er der noget undervejs, omsætning idag de første 40 minutter ca. det samme som på 7 timer igår !!

[JohnW]

Jeg tror det er MAIA, som ligger klar når FDA åbner.

[E_L]

SGEN had quarterly earnings yesterday and said a few words about Tisotumab. Nothing we don't know yet I think. transcript: https://seekingalpha.com/article/4256999-seattle-genetics-inc-sgen-ceo-clay-siegall-q1-2019-results-earnings-call-transcript?part=single

[E_L]

i'll post the main paragraph:

[E_L]

Tisotumab vedotin or TV is and ADC that we are developing in partnership with Genmab. We are conducting a pivotal Phase 2 single-arm single-agent trial for women with recurrent or metastatic cervical cancer which has recently completed enrollment and is designed to support a regular submission under the FDA's accelerated approval mechanism.

[E_L]

The primary endpoint of this trial is confirmed objective response rate by independent review. Updated data from the Phase 1 trial were recently reported at the Society of Gynecologic Oncology annual meeting showing a 22% confirmed objective response rate by independent review with a median duration of response of six months.

[E_L]

The safety profile of TV was as previously reported. We remain encouraged by the data in the setting where there is no standard of care and outcomes are poor.

[E_L]

We and Genmab are also evaluating TV in combination with other agents to inform our strategy of moving TV into earlier lines of cervical cancer. Further, we are enrolling patients in trials of TV with other solid tumors.

[E_L]

end quote

[Bulder]

Nice to hear that they have designed the trial for RTOR.

[JohnW]

Thanks E L. That was good news.

[E_L]

@Bulder yes, that shows good faith

[JKY_VH]

Tak E L

[E_L]

@Sukkeralf did you see BMS say anything about Humax IL8 in their earnings?

[Sukkeralf]

I havent looked but would guess not

[bibob]

God formiddag fra 10 km højde på vej sydpå. :-). Jeg kan se Genmab også lettede på vej nordpå. :-).

[E_L]

ok, just because you came with the links just after their earnings

[E_L]

Dr. Durie on Dara SC in the middle of the video
(again nothing we don't know...) https://www.youtube.com/watch?v=a8_MB7o0MZo

[Sukkeralf]

Bulder RTOR ?

[Sukkeralf]

From SG transcript: GSK has some fantastic data in multiple myeloma with the BCMA antibody drug conjugate. And what we hear from them is they're planning to submit in the second half of this year. And we're delighted through the impact in multiple myeloma. That is a potential large market. And they also are doing many other trials, including frontline. And so, that potentially could be a really big drug for GSK and really beneficial to patients and to Seattle genetics.